Search

Neisseria meningitidis group A capsular polysaccharide tetanus toxoid conjugate antigen

Neisseria meningitidis group C capsular polysaccharide tetanus toxoid conjugate antigen

Efzofitimod

It is a selective modulator of neuropilin-2 that downregulates the innate and adaptive immune response in inflammatory disease states.

Chiauranib

Chiauranib is under investigation in clinical trial NCT03974243 (Chiauranib in Combination With Chidamide in Patients With Relapsed/refractory Non-hodgkin's Lymphoma).

Basic Fibroblast Growth Factor

The growth factor is an extremely potent inducer of DNA synthesis in a variety of cell types from mesoderm and neuroectoderm lineages. … Although it is not approved for use in Canada or the USA, bFGF is currently undergoing investigation in a number of clinical trials.

Arsthinol

Arsthinol (INN) is an antiprotozoal agent that was first synthesized by Ernst A.H. Friedheim in 1949 via the complexing of acetarsol with 2,3-dimercaptopropanol.

Neisseria meningitidis group W-135 capsular polysaccharide tetanus toxoid conjugate antigen

CYNK-001

CYNK-001 is a novel allogenic off-the-shelf natural killer (NK) cell therapy originating from human placental CD34+ hematopoietic stem cells and enriched with CD56+/CD3-.

Andusomeran

Andusomeran is a COVID-19 mRNA vaccine developed for use during the 2023-2024 season. It is similar to previous mRNA vaccines developed by Moderna (e.g. elasomeran, imelasomeran), but is designed to be effective against the Omicron XBB.1...

Roxithromycin

It is marketed in Australia as a treatment for respiratory tract, urinary and soft tissue infections.